文献速递胸部肿瘤放疗

心脏剂量与局部晚期非小细胞肺癌的免疫抑制及不良生存相关

Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2018-05-30

该研究纳入2001至2016年接受根治性放疗±化疗的400例局部晚期非小细胞肺癌患者,分析心脏剂量与淋巴细胞减少等免疫抑制指标及生存的关系。多因素分析显示,心脏V50与总生存降低相关,心脏V50>25%与放疗后4个月NLR>10.5相关,NLR>10.5与总生存和无远处转移生存降低相关。

要点

  • 心脏V50与总生存降低独立相关(HR 1.02;95% CI 1.01-1.03)。
  • 心脏V50>25%与放疗后4个月NLR>10.5相关(HR 2.0;95% CI 1.1-3.5;p=0.02)。
  • NLR>10.5与总生存降低(p<0.001)和无远处转移生存降低(p=0.04)相关。

核心结论

  • 放疗相关免疫抑制与患者不良结局相关,可能代表除心脏毒性外的另一死亡原因。

研究设计与样本

  • 研究识别了2001年至2016年间接受根治性放疗±化疗的400例局部晚期非小细胞肺癌患者。
  • 分析放疗前、放疗期间和放疗后的绝对淋巴细胞计数、绝对中性粒细胞计数及中性粒细胞与淋巴细胞比值。
  • 采用多因素分析评估临床因素与血液学毒性和总生存的相关性,并选择上三分位阈值将连续血液学变量二分类。

主要发现

  • 全部患者中位随访17个月(范围0.2-174个月),生存者中位随访46个月(范围0.2-161个月)。
  • 94%的患者为III期疾病,77%接受同步放化疗。
  • 2年总生存、无局部复发生存和无远处转移生存分别为42%、60%和45%,中位生存18个月。
  • 总生存多因素分析(n=207)中,男性(HR 1.7;95% CI 1.2-2.3)、单纯放疗(HR 2.1;95% CI 1.9-4.0)、心脏V50(HR 1.02;95% CI 1.01-1.03)和4个月时较高NLR(HR 1.02;95% CI 1.01-1.03)与总生存降低相关;ALC最低值与治疗结局无关。
  • NLR>10.5与总生存降低(p<0.001)和无远处转移生存降低(p=0.04)相关。

关键数值与推荐

  • 总生存多因素分析(n=207)中,男性HR 1.7(95% CI 1.2-2.3),单纯放疗HR 2.1(95% CI 1.9-4.0),心脏V50 HR 1.02(95% CI 1.01-1.03),4个月时NLR HR 1.02(95% CI 1.01-1.03)。
  • NLR>10.5与总生存降低相关(p<0.001),与无远处转移生存降低相关(p=0.04)。
  • 血液学毒性多因素分析(n=247)中,辅助化疗HR 2.6(95% CI 1.3-5.0;p=0.006),单纯放疗HR 3.6(95% CI 1.1-12;p=0.04),心脏V50>25% HR 2.0(95% CI 1.1-3.5;p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Studies have associated increased radiation therapy (RT) heart dose with cardiac toxicity. Others have correlated RT-related immunosuppression with worsened survival. Given the large vascular volumes irradiated during locally advanced non-small cell lung cancer (LA-NSCLC) treatment, we hypothesized an association between increased heart dose and immunosuppression. METHODS: We identified 400 LA-NSCLC patients treated with definitive RT ± chemotherapy between 2001 and 2016. Absolute lymphocyte counts (ALC), absolute neutrophil counts (ANC), and neutrophil-to-lymphocyte ratio (NLR = ANC/ALC) were analyzed pre-RT, during RT, and post-RT. Multivariable analysis (MVA) was performed to correlate Clinical factors with both hematologic toxicity and overall survival. An upper tertile threshold to increase specificity of NLR was chosen to dichotomize continuous hematologic variables. RESULTS: Median follow up was 17 months (range 0.2-174 months) in all patients and 46 months (range 0.2-161 months) in survivors. A total of 94% of patients had stage III disease and 77% received concurrent chemo radiation. Two-year overall survival (OS), freedom from local recurrence (FFLR), and freedom from distant metastases (FFDM) was 42%, 60% and 45%, respectively. Median survival was 18 months. On MVA for OS (n = 207), male gender (Hazard Ratio [HR] 1.7; 95% CI 1.2-2.3), RT alone (HR 2.1; 95% CI 1.9-4.0), the percentage of heart receiving ≥50 Gy (V50) (HR 1.02; 95% CI 1.01-1.03), and higher NLR at 4 months (HR 1.02, 95% CI 1.01-1.03) were associated with reduced OS. ALC nadir was not associated with treatment outcomes. NLR >10.5 was associated with decreased OS (p < 0.001) and decreased FFDM (p = 0.04). On MVA evaluating factors associated with hematological toxicity (n = 247), adjuvant chemotherapy (HR 2.6; 95% CI 1.3-5.0; p = 0.006), RT alone (HR 3.6; 95% CI 1.1-12; p = 0.04), and heart V50 >25% (HR 2.0; 95% CI 1.1-3.5; p = 0.02) were associated with a NLR >10.5 4 months post-RT. CONCLUSION: RT related immunosuppression is associated with worse patient outcomes, and may represent a source of increased mortality beyond cardiac toxicity alone.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Contreras JA, Lin AJ, Weiner A, et al. Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2018. PMID: 29859754. doi:10.1016/j.radonc.2018.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。